Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic cell vaccination plus donor lymphocyte infusion in relapsed multiple myeloma after allogeneic SCT
NL-OMON26115Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2006
- Modality
- Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous dendritic cell vaccine and donor lymphocytes in multiple myeloma (MM), sponsored by University Medical Center Utrecht. Primary endpoint: Toxicity. Started Aug 2006; status: recruiting.
02
Drugs
autologous dendritic cell vaccinedonor lymphocytes
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON26115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26115.